ImmunityBio: A Speculative Theorem

Trading volume reached 176 million shares, a figure exceeding the three-month average by an order of magnitude. This, of course, is merely a numerical artifact, a symptom of the underlying irrationality that governs these exchanges. The company, having emerged in 2015, has experienced a decline of 85% since its initial public offering—a reminder that even the most promising trajectories are susceptible to the whims of chance. One is reminded of Zeno’s paradox, where the arrow, though in motion, never truly reaches its destination.








